Amplify Weight Loss Drug ... (THNR)

NYSEArca: THNR · Real-Time Price · USD

26.46

+0.25 (0.95%)

At close: Aug 18, 2026, 10:57 AM

0.95% (1D)

Bid	10.64
Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Beta	n/a
EPS (ttm)	n/a
PE Ratio (ttm)	19.16
Forward PE	n/a
P/B (ttm)	n/a
P/S (ttm)	n/a
Earnings Date	n/a

Ask	42.07
Volume	4,637
Avg. Volume (20D)	2,067
Open	26.39
Previous Close	26.21
Day's Range	26.39 - 26.46
52-Week Range	22.63 - 27.28
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About THNR

The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, includ...

[Read more]

Industry n/a

Sector n/a

IPO Date May 21, 2024

Employees n/a

Stock Exchange NYSEArca

Ticker Symbol THNR

Full Company Profile

Financial Performance

In undefined, Amplify Weight Loss Drug & Treatment ETF's revenue was n/a, an increase of undefined% compared to the previous year's n/a. Earnings were n/a, an increase of undefined%.

Financial Statements

News

1 month ago · Zacks

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.